Home LanguageEnglish Global Life Science Reagents and Tools Corp. Abcam Announce Acquisition of Calico Biolabs

Global Life Science Reagents and Tools Corp. Abcam Announce Acquisition of Calico Biolabs

by Business PR
844 views

This acquisition strategically expands our leadership in recombinant rabbit monoclonal antibody technology. The combination of our complementary antibody engineering capabilities will further support our mission to provide our customers with access to the best antibodies for both today’s and tomorrow’s targets of interest.


About Abcam

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.

Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading, antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company’s pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products.

With eleven sites globally, many of Abcam’s 1,100 strong team are located in the world’s leading life science research hubs, complementing a global network of services and support.

To discover more, please visit www.abcam.com and www.abcamplc.com.

Contacts

At Abcam:
Francesca Axe
T: +44 (0)1223 696000
E: francesca.axe@abcam.com

For Media Enquiries:
Tim Watson / Dr Katie Duffell
Instinctif Partners
T: +44 (0)20 7457 2013
E: abcam@instinctif.com

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More